Life-Long Commitment: A New Study Says That Over Half of the Weight Lost Through GLP-1 Drugs Such as Zepbound Comes Back After Quitting

wccftech.com:

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.

GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI.

Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce the overall food intake. Concurrently, GLP-1 receptors also suppress the brain's stress response and reward/reinforcement mechanism to increase the feeling of satiation. Over time, patients can reduce their daily caloric intake by around 20 percent, leading to significant weight loss.

MORGAN STANLEY: “.. 5% of the US population is taking #GLP1 drugs, with 11.4% of households having at least one member currently taking GLP-1s ..” [Huberty] $LLY $NVO $CPB $HSY pic.twitter.com/p2VyDvJQnW

— Carl Quintanilla (@carlquintanilla) December 5, 2023

Morgan Stanley recently estimated that around 11 percent of US households - corresponding to roughly 5 percent of the total population - currently have at least one member on a weekly regimen of GLP-1 drugs, with another 17 percent of the